Journal profile · Immunology
Cancer Immunology Immunotherapy
ISSN 0340-7004 · eISSN 1432-0851 · Springer Berlin Heidelberg · UNITED STATES · Monthly · Founded 1976
Cancer Immunology Immunotherapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.75; fully open access; APC about USD 4,790; median 107 days to acceptance (95 articles, last 24 months); community-reported acceptance: fairly easy; 374 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Immunology Immunotherapy is published by Springer Berlin Heidelberg and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers and Immune Cell Function and Interaction, together about 48.4% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), Sociedad Española de Immunologia-Grupo Español de ImmunoTerapia (SEI-GEIT), and Cancer Immunotherapy & Immunomonitoring (CITIM).
From the journal's Aims & Scope
Research area (LetPub): Immunology
Editor-in-chief Haidong DongPublisher website
Editorial board by country: 8 in mainland China (about 21%); most named United States 13, Mainland China 8, Germany 4, United Kingdom 3, Italy 3 (39 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology20.1%
- Cancer Immunotherapy and BiomarkersMedicine14.8%
- Immune Cell Function and InteractionImmunology and Microbiology13.6%
- CAR-T cell therapy researchMedicine7.9%
- T-cell and B-cell ImmunologyImmunology and Microbiology6.8%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.1%
- Immune cells in cancerImmunology and Microbiology4.9%
- Glycosylation and Glycoproteins ResearchBiochemistry, Genetics and Molecular Biology2.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, AGRICOLA, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.75LetPub ·
- Impact factor (publisher) 2025
- 5.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.6Publisher website ·
- CiteScore 2026-06
- 9.5LetPub ·
- SJR 2026-06
- 1.81LetPub ·
- SNIP 2026-06
- 1.03LetPub ·
- h-index
- 104LetPub ·
- h-index
- 166OpenAlex ·
- i10-index
- 4,964OpenAlex ·
- 2-year mean citedness
- 5.6OpenAlex ·
- Self-citation rate
- 3.4%LetPub ·
- Share of gold OA articles
- 87.15%LetPub ·
Volume
- Articles per year
- 359LetPub ·
- Downloads per year (publisher) 2025
- 2,300,000Publisher website ·
Articles by year OpenAlex count · 7,732 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 306 | 306 | 184 |
| 2025 | 374 | 374 | 1,874 |
| 2024 | 301 | 301 | 3,437 |
| 2023 | 223 | 223 | 3,698 |
| 2022 | 233 | 233 | 5,145 |
| 2021 | 320 | 318 | 9,029 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
107 daysMedian, submission to acceptance · P25–P75 70 days – 154 days
- Acceptance to online
- median 22 days (95 articles)
- Submission to online
- median 137 days
- Sample
- 95 articles with submission and acceptance dates (727 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,590 / USD 4,790 / GBP 2,990 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,590 / EUR 3,490 / GBP 2,890 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
- Tumour Immune MicroenvironmentDeadline
- Immune Metabolism in CancerDeadline
- CAR MacrophageDeadline
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted15, with length limits
- brief research reportsBrief research reports – featuring clear and concise conclusion supported by solid data at small-scale basic research or early stage of clinical studies, 2000 w…Length not stated
- clinical trial reportsClinical Trial Reports – please review the guidelines of Original research Articles and include relevant immunological data.Length not stated
- commentaryThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- editorialThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- editorialsEditorials- it is a forum for exchanging ideas, innovations, new updates in a fast-moving field or topic. Word limitation 1200 with up to 10 references and one …Length not stated
- letterThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- letter to the editorsLetter to the Editors – This journal occasionally accepts letters to the Editors pertaining primarily to articles published in the Journal. Text is limited to 7…Length not stated
- meta-analysisThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- meta-analysis reviewsMeta-analysis Reviews - Must be based on a rigorous methodological/statistical approach described in detail in the methods section applied to a relevant clinica…Length not stated
- opinionThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- original research articleThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- original research articlesOriginal research articles – featuring three innovations: new concept, new mechanism or new therapy, in basic science and clinical studies, text limit 4000 word…Length not stated
- research reportThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
- reviewThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…main text ≤ 4,000 words
- systematic reviewThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship, Criteria and Contributions
All authors must approve all versions of a submitted manuscript. All authors of accepted articles must accept responsibility for the manuscript’s content by signing an authorship form affirming that they have met the following three criteria for authorship: 1. Substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of results. 2. Substantial scie…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data Availability
Optional data availability statement encouraged. Model summary
This journal encourages authors to provide an optional statement of data availability in their article. Data Availability Statements should include information on where data supporting the results reported in the article can be found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. Data availability statements can also indicate whether …
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
Originality and co-author approval required at submission. Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Articles in Springer Nature open access journals do not require transfer of copyright as the copyright remains with the author. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Cancer Immunology, Immunotherapy, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Single-blind peer review
Single-blind peer review Model summary
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Berlin Heidelberg
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1976
- ISSN
- 0340-7004
- Electronic ISSN
- 1432-0851
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
FAQ
Frequently asked questions about Cancer Immunology Immunotherapy
What CAS zone is Cancer Immunology Immunotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Immunology Immunotherapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Immunology / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Immunology Immunotherapy?
The latest impact factor listed by LetPub is 5.75; CiteScore 9.5, h-index 166.
How long does peer review take at Cancer Immunology Immunotherapy?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 107 days (interquartile range 70–154 days); authors report an average review time of about 1 month; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Immunology Immunotherapy?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Immunology Immunotherapy based?
Of the 39 board members whose country the journal's board page names, 8 (about 21%) are in mainland China; the countries named most often are United States (13), Mainland China (8) and Germany (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Immunology Immunotherapy?
According to LetPub and DOAJ records, Cancer Immunology Immunotherapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Cancer Immunology Immunotherapy open access, and what is the APC?
Cancer Immunology Immunotherapy is a fully open-access journal. APC about USD 4,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .